BI 3821001

BI-3821001 · Boehringer Ingelheim

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BI 3821001, covering 2026-04-13 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: A Study in Healthy Men to Test How Well Different Doses of BI 3821001 Are Tolerated [Phase 1]